Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Hussein, O. Bock, A. Seegers, M. Flasshove, F. Henneke, G. Buesche, H. Kreipe (2007)
Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation.Blood, 109 9
A. Fiorini, G. Farina, G. Reddiconto, M. Palladino, E. Rossi, T. Za, L. Laurenti, S. Giammarco, P. Chiusolo, G. Leone, S. Sica (2006)
Screening of JAK2 V617F mutation in multiple myelomaLeukemia, 20
R. Kralovics, F. Passamonti, A. Buser, Soon-Siong Teo, R. Tiedt, J. Passweg, A. Tichelli, M. Cazzola, R. Skoda (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders.The New England journal of medicine, 352 17
Ruriko Tanaka, J. Kuroda, W. Stevenson, E. Ashihara, T. Ishikawa, T. Taki, Yutaka Kobayashi, Y. Kamitsuji, E. Kawata, M. Takeuchi, Y. Murotani, A. Yokota, M. Hirai, Satoshi Majima, M. Taniwaki, T. Maekawa, S. Kimura (2008)
Fully automated and super-rapid system for the detection of JAK2V617F mutation.Leukemia research, 32 9
Arlen Pm, Goldkland Ga (1995)
Multiple myeloma after treatment of essential thrombocythemia.Southern Medical Journal, 88
R. Levine, M. Wadleigh, J. Cools, B. Ebert, G. Wernig, B. Huntly, T. Boggon, I. Wlodarska, Jennifer Clark, Sandra Moore, Jennifer Adelsperger, Sumin Koo, Jeffrey Lee, S. Gabriel, T. Mercher, A. D’Andrea, S. Fröhling, K. Döhner, P. Marynen, P. Vandenberghe, R. Mesa, A. Tefferi, J. Griffin, M. Eck, W. Sellers, M. Meyerson, T. Golub, Stephanie Lee, D. Gilliland (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.Cancer cell, 7 4
Ana Gabrea, P. Bergsagel, W. Kuehl (2006)
Distinguishing primary and secondary translocations in multiple myeloma.DNA repair, 5 9-10
O. Selroos, A. Assendelft (2009)
Thrombocythaemia and multiple myeloma. A report on two cases.Acta medica Scandinavica, 201 3
A. Tefferi (2006)
Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.Hematology. American Society of Hematology. Education Program
C. Jamieson, J. Gotlib, J. Durocher, M. Chao, M. Mariappan, Marla Lay, Carol Jones, J. Zehnder, S. Lilleberg, I. Weissman (2006)
The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.Proceedings of the National Academy of Sciences of the United States of America, 103 16
L. Barber, Rosemary Barlow, S. Meyer, D. White, A. Will, T. Eden, G. Taylor (2005)
Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2V617F in granulocytesBritish Journal of Haematology, 130
Felipe Prosper, J. Borbolla, J. Rifón, B. Cuesta, Javier Fernández, A. Pinacho, E. Rocha (1992)
Coexistence of essential thrombocythemia and multiple myelomaAnnals of Hematology, 65
R. Hoffman, J. Prchal, S. Samuelson, S. Ciurea, D. Rondelli (2007)
Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 13 1 Suppl 1
R. Kralovics, Soon-Siong Teo, Sai Li, A. Theocharides, A. Buser, A. Tichelli, R. Skoda (2006)
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.Blood, 108 4
松山 智洋 (2005)
What's going on 造血器腫瘍 A gain-of-function mutation of JAK2 in myeloproliferative disorders. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. N Engl J Med. 2005; 352: 1779-90. PMID:15858187.--慢性骨髄増殖性疾患においてJAK2遺伝子の変異が高頻度にみられることを示した論文, 2
P. Kelsey, K. Patel (1995)
Essential thrombocythaemia followed by multiple myeloma in the same patient.Clinical and laboratory haematology, 17 4
M. Inami, K. Inokuchi, Masahiro Okabe, F. Kosaka, Y. Mitamura, Hiroki Yamaguchi, K. Dan (2007)
Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemiaLeukemia, 21
A. Candoni, M. Tiribelli, R. Fanin (2004)
Plasma Cell Leukemia Occurring in a Patient with Thrombocythemia Treated with Hydroxyurea and BusulphanLeukemia & Lymphoma, 45
R. Kyle, J. Child, K. Anderson, B. Barlogie, R. Bataille, W. Bensinger, J. Bladé, M. Boccadoro, W. Dalton, M. Dimopoulos, B. Djulbegovic, M. Drayson, B. Durie, T. Facon, R. Fonseca, G. Gahrton, P. Greipp, J. Harousseau, D. Harrington, M. Hussein, D. Joshua, H. Ludwig, G. Morgan, M. Oken, R. Powles, P. Richardson, D. Roodman, J. Miguel, K. Shimizu, C. Shustik, B. Sirohi, P. Sonneveld, G. Tricot, I. Turesson, B. Ness, D. Vesole, D. Weber, J. Westin, K. Wheatley (2003)
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working GroupBritish Journal of Haematology, 121
N. Curtin, P. Campbell, A. Green (2005)
The Philadelphia translocation and pre‐existing myeloproliferative disordersBritish Journal of Haematology, 128
N. Majhail, A. Lichtin (2003)
Rare coexistence of multiple myeloma with essential thrombocythemia: report of two cases.Haematologica, 88 4
K. Nishida, A. Tamura, N. Nakazawa, Y. Ueda, T. Abe, F. Matsuda, Keiichi Kashima, M. Taniwaki (1997)
The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization.Blood, 90 2
D. Gonzalez, M. Burg, R. García-Sanz, J. Fenton, A. Langerak, Marcos González, J. Dongen, J. Miguel, G. Morgan (2007)
Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma.Blood, 110 9
Overlapping of essential thrombocythemia (ET) and multiple myeloma (MM) has been extremely rare. Our report concerns a case with concomitant ET and MM, where JAK2V617F was present in non-myeloma peripheral blood leukocytes and bone marrow (BM) hematopoietic cells, but not in BM-derived CD138-positive myeloma cells. In contrast, double-color fluorescence in situ hybridization analysis showed that BM-derived CD138-positive myeloma cells possessed the gene translocation between the immunoglobulin heavy chain gene and the cyclin D1 gene, which was not involved in non-myeloma hematopoietic cells. This is the first case with concomitant ET and MM in which the 2 hematologic neoplasms were shown to have originated from separate malignant clones at hierarchically different differentiation levels resulting from independent acquisition of different molecular aberrations. Among the 10 reported cases, including ours, ET preceded MM in 8 cases, but MM never preceded ET. We suggest that MM clones may have greater proliferative potency compared with ET clones, and that the treatment modification from ET to MM did not seem to exacerbate ET in most reported cases, perhaps because of the suppression of the ET clone by both the cytotoxic effect of anti-myeloma therapy and the clonal repression by MM progression.
Acta Haematologica – Karger
Published: Jan 1, 2008
Keywords: Double-color fluorescence in situ hybridization; Essential thrombocythemia; IGH/CCND1; JAK2V617F; Multiple myeloma
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.